Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 319,577
  • Shares Outstanding, K 135,990
  • Annual Sales, $ 6,790 K
  • Annual Income, $ -128,530 K
  • 36-Month Beta 2.57
  • Price/Sales 25.56
  • Price/Cash Flow N/A
  • Price/Book 1.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.23 +6.73%
on 02/09/18
2.90 -17.93%
on 01/29/18
-0.38 (-13.77%)
since 01/19/18
3-Month
2.23 +6.73%
on 02/09/18
3.09 -22.98%
on 12/11/17
-0.48 (-16.78%)
since 11/20/17
52-Week
2.20 +8.18%
on 06/08/17
3.94 -39.59%
on 03/06/17
-1.11 (-31.81%)
since 02/17/17

Most Recent Stories

More News
Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, Inc. (NASDAQ:WDAY),...

CLDX : 2.39 (+1.70%)
LCI : 16.75 (-1.76%)
MDCO : 32.77 (-1.18%)
ATRS : 2.28 (-4.60%)
WDAY : 126.80 (+2.25%)
OCLR : 6.89 (+0.29%)
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

CLDX : 2.39 (+1.70%)
ABBV : 120.68 (+1.75%)
REGN : 328.72 (-1.03%)
SNY : 39.82 (-0.23%)
Amgen Announces Acceptance of MAA for Evenity in Europe

Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.

CLDX : 2.39 (+1.70%)
CATB : 1.55 (-3.13%)
MRK : 55.41 (-1.56%)
AMGN : 183.97 (+0.23%)
Ultragenyx Announces Interim Data from Early Stage Study

Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.

CLDX : 2.39 (+1.70%)
CATB : 1.55 (-3.13%)
RARE : 49.77 (+5.62%)
ANTH : 1.71 (+1.18%)
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio

Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.

CLDX : 2.39 (+1.70%)
MRK : 55.41 (-1.56%)
JUNO : 85.30 (+0.24%)
BMY : 68.09 (-1.26%)
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.

CORT : 15.65 (-2.07%)
CLDX : 2.39 (+1.70%)
ACAD : 31.56 (+2.07%)
TXMD : 5.46 (-2.15%)
Biotech's Sprinting Into the New Year

As we near the end of 2017, biotech companies are preparing for the first quarter of the New Year. As time progresses we continue to witness technology change lives in every possible way, biotechnology...

SPPI : 20.71 (-2.13%)
LJPC : 34.38 (+1.51%)
CLDX : 2.39 (+1.70%)
ENDV : 0.0510 (+8.51%)
GILD : 81.49 (+0.98%)
This Morning's Technical Outlook on Biotech Stocks -- Alnylam Pharma, Celldex Therapeutics, Aduro BioTech, and Zosano Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ALNY, CLDX, ADRO, and ZSAN which can be accessed for free by signing up to http://www.wallstequities.com/registration....

CLDX : 2.39 (+1.70%)
ALNY : 122.71 (-0.14%)
ZSAN : 4.47 (+4.17%)
ADRO : 6.15 (+1.65%)
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study

AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.

CLDX : 2.39 (+1.70%)
LLY : 78.22 (-0.95%)
INCY : 86.79 (+0.88%)
ABBV : 120.68 (+1.75%)
Minerva Initiates Phase III Study on Schizophrenia Candidate

Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.

CLDX : 2.39 (+1.70%)
JNJ : 131.60 (-1.16%)
ACAD : 31.56 (+2.07%)
NERV : 5.38 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 2.44
1st Resistance Point 2.39
Last Price 2.39
1st Support Level 2.31
2nd Support Level 2.28

See More

52-Week High 3.94
Fibonacci 61.8% 3.28
Fibonacci 50% 3.07
Fibonacci 38.2% 2.86
Last Price 2.39
52-Week Low 2.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.